uniQure (NASDAQ:QURE) Given Average Rating of “Moderate Buy” by Brokerages

uniQure (NASDAQ:QURE) has been given a consensus recommendation of “Moderate Buy” by the seven analysts that are covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $23.50.

QURE has been the subject of several recent analyst reports. HC Wainwright restated a “buy” rating and issued a $25.00 price target on shares of uniQure in a report on Tuesday, July 9th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $24.00 target price on shares of uniQure in a research report on Tuesday, July 16th. Finally, Mizuho cut their target price on uniQure from $7.00 to $6.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 8th.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Raymond James & Associates grew its holdings in uniQure by 6.4% in the 4th quarter. Raymond James & Associates now owns 52,224 shares of the biotechnology company’s stock valued at $354,000 after buying an additional 3,145 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its stake in shares of uniQure by 58.5% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,922 shares of the biotechnology company’s stock valued at $52,000 after buying an additional 3,664 shares during the period. Pale Fire Capital SE increased its stake in shares of uniQure by 9.2% in the 4th quarter. Pale Fire Capital SE now owns 65,600 shares of the biotechnology company’s stock valued at $444,000 after buying an additional 5,500 shares during the period. Clear Harbor Asset Management LLC increased its stake in shares of uniQure by 35.2% in the 2nd quarter. Clear Harbor Asset Management LLC now owns 48,000 shares of the biotechnology company’s stock valued at $215,000 after buying an additional 12,500 shares during the period. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in shares of uniQure during the fourth quarter worth $86,000. Institutional investors and hedge funds own 78.83% of the company’s stock.

uniQure Price Performance

NASDAQ:QURE opened at $8.08 on Thursday. The firm’s fifty day moving average price is $5.61 and its 200 day moving average price is $5.46. uniQure has a 1-year low of $3.73 and a 1-year high of $11.35. The company has a current ratio of 9.39, a quick ratio of 9.27 and a debt-to-equity ratio of 0.70.

uniQure (NASDAQ:QURE) last released its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($1.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.31) by ($0.05). The firm had revenue of $8.49 million for the quarter, compared to analyst estimates of $2.58 million. uniQure had a negative return on equity of 121.60% and a negative net margin of 1,562.22%. Sell-side analysts anticipate that uniQure will post -4.4 earnings per share for the current fiscal year.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.